Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPS-2071 add-on therapy for active Crohn's disease
2019-000176-41Phase 2Terminated
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Aug 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of OPS-2071 in Crohn's disease (4 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Clinical remission at Week 12. Started Aug 2019; status: terminated.
02
Drugs
OPS-2071
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2019-000176-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000176-41.